396 related articles for article (PubMed ID: 22100015)
1. Recent advances in the treatment of Kawasaki disease.
Weng KP; Ou SF; Lin CC; Hsieh KS
J Chin Med Assoc; 2011 Nov; 74(11):481-4. PubMed ID: 22100015
[TBL] [Abstract][Full Text] [Related]
2. Kawasaki disease: a comprehensive review of treatment options.
Patel RM; Shulman ST
J Clin Pharm Ther; 2015 Dec; 40(6):620-5. PubMed ID: 26547265
[TBL] [Abstract][Full Text] [Related]
3. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
Jone PN; Anderson MS; Mulvahill MJ; Heizer H; Glodé MP; Dominguez SR
Pediatr Infect Dis J; 2018 Oct; 37(10):976-980. PubMed ID: 29461447
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.
Lei WT; Chang LS; Zeng BY; Tu YK; Uehara R; Matsuoka YJ; Su KP; Lee PC; Cavalcante JL; Stubbs B; Lin PY; Wu YC; Hsu CW; Chen TY; Chen YW; Yeh PY; Sun CK; Tseng PT; Kao YH
EBioMedicine; 2022 Apr; 78():103946. PubMed ID: 35306339
[TBL] [Abstract][Full Text] [Related]
5. Management of acute and refractory Kawasaki disease.
Tacke CE; Burgner D; Kuipers IM; Kuijpers TW
Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1203-15. PubMed ID: 23199405
[TBL] [Abstract][Full Text] [Related]
6. A Multicenter Study of Intravenous Immunoglobulin Non-response in Kawasaki Disease.
Wei M; Huang M; Chen S; Huang G; Huang M; Qiu D; Guo Z; Jiang J; Zhou X; Yu Q; Guo Y; Fu L; Gao W; Li F
Pediatr Cardiol; 2015 Aug; 36(6):1166-72. PubMed ID: 25812827
[TBL] [Abstract][Full Text] [Related]
7. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol.
Eleftheriou D; Moraes YC; Purvis C; Pursell M; Morillas MM; Kahn R; Mossberg M; Kucera F; Tulloh R; Standing JF; Swallow V; McCormack R; Herberg J; Levin M; Wan M; Klein N; Connon R; Walker AS; Brogan P
Trials; 2023 Jan; 24(1):60. PubMed ID: 36703139
[TBL] [Abstract][Full Text] [Related]
8. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
Kuo HC; Lo MH; Hsieh KS; Guo MM; Huang YH
PLoS One; 2015; 10(12):e0144603. PubMed ID: 26658843
[TBL] [Abstract][Full Text] [Related]
9. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
Qiu H; He Y; Rong X; Ren Y; Pan L; Chu M; Wu R; Shi H
Postgrad Med; 2018 May; 130(4):442-447. PubMed ID: 29745742
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of monocyte to HDL-C ratio for coronary artery lesions and intravenous immunoglobulin resistance in Kawasaki disease.
Wang JR; Zhao HZ; Chang LJ; Xu X; Gao Y; Li M; Kong QY; Wang MM; Zhao CF
Eur J Pediatr; 2023 Oct; 182(10):4399-4406. PubMed ID: 37480545
[TBL] [Abstract][Full Text] [Related]
11. Kawasaki disease: 40 years after the original report.
Gedalia A
Curr Rheumatol Rep; 2007 Aug; 9(4):336-41. PubMed ID: 17688844
[TBL] [Abstract][Full Text] [Related]
12. Association of Genetic Polymorphisms in Kawasaki Disease with the Response to Intravenous Immunoglobulin Therapy.
Sapountzi E; Fidani L; Giannopoulos A; Galli-Tsinopoulou A
Pediatr Cardiol; 2023 Jan; 44(1):1-12. PubMed ID: 35908117
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of intravenous immunoglobulin alone and intravenous immunoglobulin combined with high-dose aspirin in the acute stage of Kawasaki disease: study protocol for a randomized controlled trial.
Kuo HC; Guo MM; Lo MH; Hsieh KS; Huang YH
BMC Pediatr; 2018 Jun; 18(1):200. PubMed ID: 29933749
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of the risk factors for coronary artery lesions in Kawasaki disease.
Weng KP; Hsieh KS; Huang SH; Ou SF; Ma CY; Ho TY; Lai CR; Ger LP
Kaohsiung J Med Sci; 2012 Jan; 28(1):23-9. PubMed ID: 22226058
[TBL] [Abstract][Full Text] [Related]
15. Revisiting the role of steroids and aspirin in the management of acute Kawasaki disease.
Dhanrajani A; Yeung RSM
Curr Opin Rheumatol; 2017 Sep; 29(5):547-552. PubMed ID: 28661936
[TBL] [Abstract][Full Text] [Related]
16. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children.
Wooditch AC; Aronoff SC
Pediatrics; 2005 Oct; 116(4):989-95. PubMed ID: 16199713
[TBL] [Abstract][Full Text] [Related]
17. Elevated D-dimer level is a risk factor for coronary artery lesions accompanying intravenous immunoglobulin-unresponsive Kawasaki disease.
Masuzawa Y; Mori M; Hara T; Inaba A; Oba MS; Yokota S
Ther Apher Dial; 2015 Apr; 19(2):171-7. PubMed ID: 25257673
[TBL] [Abstract][Full Text] [Related]
18. Reevaluation of the efficacy of intravenous gammaglobulin in the prevention and treatment of coronary artery lesion in Kawasaki disease.
Qin L; Saumu MT; Wang H; Shi H; Hu X; Cheng P
J Huazhong Univ Sci Technolog Med Sci; 2005; 25(3):348-50, 370. PubMed ID: 16201293
[TBL] [Abstract][Full Text] [Related]
19. Kawasaki Disease: Beyond IVIG and Aspirin.
Moussa T; Wagner-Weiner L
Pediatr Ann; 2019 Oct; 48(10):e400-e405. PubMed ID: 31609999
[TBL] [Abstract][Full Text] [Related]
20. Kawasaki disease: part II. Complications and treatment.
Bayers S; Shulman ST; Paller AS
J Am Acad Dermatol; 2013 Oct; 69(4):513.e1-8; quiz 521-2. PubMed ID: 24034380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]